EXHIBIT 99.1

Protalex, Inc.
145 Union Square Drive
New Hope, PA 18938
(p) 215-862-9720
(f) 215-862-6614

FOR IMMEDIATE RELEASE

Contact:
Marc L. Rose
Vice President and Chief Financial Officer
(p) 215-862-9720
(f)  215-862-6614
mrose@protalex.com

                    PROTALEX APPOINTS VICTOR S. SLOAN M.D. AS
                  SENIOR VICE PRESIDENT & CHIEF MEDICAL OFFICER

      Noted Clinician in Multiple Therapeutic Areas to Lead Clinical Trials

New Hope, PA, July 26th, 2005 -- Protalex, Inc. (OTCBB: PRTX) today announced
that Victor S. Sloan, M.D., FACR, FACP has joined the company as Senior Vice
President and Chief Medical Officer. Dr. Sloan is a board certified
rheumatologist with extensive experience in designing and managing all phases of
the clinical trial process. Dr. Sloan received his A.B. from University of
Chicago (Chicago, IL), M.D. from New York Medical College (Valhalla, NY) and
attended the Belfer Institute for Advanced Biomedical Studies, Albert Einstein
College of Medicine (Bronx, NY).

Most recently, Dr. Sloan was Senior Director and Disease Area Section Head,
Arthritis at Novartis Pharmaceuticals Corporation. While at Novartis, Dr. Sloan
oversaw numerous clinical trials ranging from proof of concept through Phase
III, as well as several regulatory submissions in arthritis. Additionally, he
worked closely with research and clinical development teams in conducting due
diligence of potential in-licensed compounds.

Steven Kane, President and CEO of Protalex, said, "Dr. Sloan is a valuable
addition to our management team. His extensive experience in arthritis and other
autoimmune diseases will benefit the company greatly as we prepare to move into
the clinic with our lead compound, PRTX-100."

"Victor complements our executive group well," added G. Kirk Raab, Chairman of
the Board. "His prior leadership role at Novartis ideally positions him to
provide critical guidance for creating and leading our clinical programs, as
well as for decisions regarding Protalex's future direction."

Of the opportunity Dr. Sloan commented, "Despite recent advances in therapies
for autoimmune diseases, there remains significant unmet medical need in many
areas. I am looking forward to joining the Protalex team at this exciting time."

In addition to his industry experience, Dr. Sloan holds an appointment as
Clinical Associate Professor of Medicine, Robert Wood Johnson Medical School
(New Brunswick, NJ), and serves on the Board of Directors of both the Arthritis
Foundation, NJ Chapter, and the Lupus Foundation of America, NJ Chapter.



About Protalex

Protalex is a biotechnology company engaged in the development of a new class of
drug for the treatment of Rheumatoid Arthritis, Pemphigus and other autoimmune
diseases.

Cautionary Statement Regarding Forward Looking Information

This release contains forward-looking information about Protalex, Inc. that are
intended to be covered by the safe harbor for forward-looking statements
provided by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are statements that are not historical facts. These
statements can be identified by the use of forward-looking terminology such as
"believe," "expect," "may," "will," "should," "project," "plan," "seek,"
"intend," or "anticipate" or the negative thereof or comparable terminology, and
include discussions of strategy, statements regarding expectations or
consequences of Dr. Sloan's hiring, and statements about industry trends and
Protalex's future performance, operations and products.

Protalex's actual results could differ materially from those described in this
release. Factors that could cause or contribute to such differences include, but
are not limited to, those discussed in detail under the heading "Risk Factors"
in Protalex's Registration Statement on Form SB-2 filed with the SEC on June 16,
2005 and its other periodic reports filed with the Securities and Exchange
Commission. This forward-looking information should be considered only in
connection with the aforementioned risk factors. Protalex assumes no obligation
to update any forward-looking statements or information set forth in this press
release.